MY186523A - Macrocyclic rip2 kinase inhibitors - Google Patents
Macrocyclic rip2 kinase inhibitorsInfo
- Publication number
- MY186523A MY186523A MYPI2017700447A MYPI2017700447A MY186523A MY 186523 A MY186523 A MY 186523A MY PI2017700447 A MYPI2017700447 A MY PI2017700447A MY PI2017700447 A MYPI2017700447 A MY PI2017700447A MY 186523 A MY186523 A MY 186523A
- Authority
- MY
- Malaysia
- Prior art keywords
- kinase inhibitors
- macrocyclic
- rip2 kinase
- compounds
- rip2
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- 101150021296 rip2 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 101001109137 Homo sapiens Receptor-interacting serine/threonine-protein kinase 2 Proteins 0.000 abstract 1
- 101000733257 Homo sapiens Rho guanine nucleotide exchange factor 28 Proteins 0.000 abstract 1
- 102100022502 Receptor-interacting serine/threonine-protein kinase 2 Human genes 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000002678 macrocyclic compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14185130 | 2014-09-17 | ||
| PCT/EP2015/071347 WO2016042087A1 (en) | 2014-09-17 | 2015-09-17 | Macrocyclic rip2 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY186523A true MY186523A (en) | 2021-07-24 |
Family
ID=51687776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2017700447A MY186523A (en) | 2014-09-17 | 2015-09-17 | Macrocyclic rip2 kinase inhibitors |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10676486B2 (https=) |
| EP (1) | EP3194407B1 (https=) |
| JP (1) | JP6736545B2 (https=) |
| KR (1) | KR102563829B1 (https=) |
| CN (1) | CN106687464B (https=) |
| AU (1) | AU2015316799B2 (https=) |
| BR (1) | BR112017004035B1 (https=) |
| CA (1) | CA2958782C (https=) |
| DK (1) | DK3194407T3 (https=) |
| EA (1) | EA032872B1 (https=) |
| ES (1) | ES2763344T3 (https=) |
| HR (1) | HRP20192334T1 (https=) |
| HU (1) | HUE048518T2 (https=) |
| IL (1) | IL250544B (https=) |
| LT (1) | LT3194407T (https=) |
| MX (1) | MX376087B (https=) |
| MY (1) | MY186523A (https=) |
| PL (1) | PL3194407T3 (https=) |
| PT (1) | PT3194407T (https=) |
| SA (1) | SA517381087B1 (https=) |
| SG (1) | SG11201701116XA (https=) |
| SI (1) | SI3194407T1 (https=) |
| TW (1) | TWI709563B (https=) |
| UA (1) | UA121315C2 (https=) |
| WO (1) | WO2016042087A1 (https=) |
| ZA (1) | ZA201701331B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102719387B1 (ko) * | 2017-01-26 | 2024-10-21 | 한미약품 주식회사 | 이미다조피리다진 화합물 |
| UA129879C2 (uk) | 2020-01-31 | 2025-08-27 | Онкодизайн Пресіжн Медісін (Опм) | Макроциклічні інгібітори rip2-кінази |
| JP2025532532A (ja) * | 2022-09-07 | 2025-10-01 | 蘇州朗睿生物医薬有限公司 | 大環状イミダゾ［１，２－ｂ］ピリダジン誘導体並びにその調製方法及び用途 |
| WO2024146541A1 (en) * | 2023-01-03 | 2024-07-11 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Macrocyclic compounds as usp1 inhibitors |
| WO2025212514A2 (en) * | 2024-04-02 | 2025-10-09 | Interline Therapeutics, Inc. | Methods of treating inflammatory diseases |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| SK283569B6 (sk) | 1993-10-01 | 2003-09-11 | Astra Aktiebolag | Spôsob spracovania jemne deleného práškového liečiva, zariadenie na vykonávanie tohto spôsobu a aglomeráty vyrobené týmto spôsobom |
| US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| BRPI0718029A2 (pt) * | 2006-11-06 | 2013-11-26 | Supergen Inc | Derivados de imidazo(1,2-b)piridazina e pirazolo(1,5-a)pirimidina e seu uso como inibidores da proteína cinase |
| AR077468A1 (es) * | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| NZ604708A (en) * | 2010-05-20 | 2015-05-29 | Array Biopharma Inc | Macrocyclic compounds as trk kinase inhibitors |
| WO2013001310A1 (en) * | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| CA2849999A1 (en) | 2011-09-30 | 2013-04-04 | Oncodesign S.A. | Macrocyclic flt3 kinase inhibitors |
| BR112014007654A8 (pt) | 2011-09-30 | 2018-06-12 | Ipsen Pharma | Inibidores de lrrk2 quinase macrocíclicos. |
-
2015
- 2015-09-17 CN CN201580050163.3A patent/CN106687464B/zh active Active
- 2015-09-17 PL PL15766800T patent/PL3194407T3/pl unknown
- 2015-09-17 US US15/505,976 patent/US10676486B2/en active Active
- 2015-09-17 JP JP2017514486A patent/JP6736545B2/ja active Active
- 2015-09-17 SG SG11201701116XA patent/SG11201701116XA/en unknown
- 2015-09-17 KR KR1020177010128A patent/KR102563829B1/ko active Active
- 2015-09-17 TW TW104130751A patent/TWI709563B/zh active
- 2015-09-17 HU HUE15766800A patent/HUE048518T2/hu unknown
- 2015-09-17 DK DK15766800.5T patent/DK3194407T3/da active
- 2015-09-17 AU AU2015316799A patent/AU2015316799B2/en active Active
- 2015-09-17 EA EA201790609A patent/EA032872B1/ru unknown
- 2015-09-17 MX MX2017003469A patent/MX376087B/es active IP Right Grant
- 2015-09-17 PT PT157668005T patent/PT3194407T/pt unknown
- 2015-09-17 WO PCT/EP2015/071347 patent/WO2016042087A1/en not_active Ceased
- 2015-09-17 CA CA2958782A patent/CA2958782C/en active Active
- 2015-09-17 BR BR112017004035-2A patent/BR112017004035B1/pt active IP Right Grant
- 2015-09-17 MY MYPI2017700447A patent/MY186523A/en unknown
- 2015-09-17 LT LTEP15766800.5T patent/LT3194407T/lt unknown
- 2015-09-17 UA UAA201703558A patent/UA121315C2/uk unknown
- 2015-09-17 EP EP15766800.5A patent/EP3194407B1/en active Active
- 2015-09-17 SI SI201531050T patent/SI3194407T1/sl unknown
- 2015-09-17 ES ES15766800T patent/ES2763344T3/es active Active
- 2015-09-17 HR HRP20192334TT patent/HRP20192334T1/hr unknown
-
2017
- 2017-02-09 IL IL250544A patent/IL250544B/en active IP Right Grant
- 2017-02-22 ZA ZA2017/01331A patent/ZA201701331B/en unknown
- 2017-03-14 SA SA517381087A patent/SA517381087B1/ar unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015011359A (es) | Inhibidores macrociclicos de cinasa 2 de repeticion rica en leucina (lrrk2). | |
| MX2015012526A (es) | Inhibodores macrociclicos de cinasa rip2. | |
| MX2015012528A (es) | Inhibidores macrociclicos de cinasa inducibles por sal. | |
| MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
| PH12017501921A1 (en) | Novel compounds | |
| PH12017500802B1 (en) | Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof | |
| PH12017500453A1 (en) | Spirocyclic inhibitors of cathepsin c | |
| TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
| MX370792B (es) | Composiciones para usarse en el tratamiento de cáncer. | |
| PH12016502355A1 (en) | Pharmaceutical composition | |
| MX2017003470A (es) | Inhibidores macrociclicos de cinasa lrrk2. | |
| TW201613578A (en) | Pharmaceutical combinations | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| MY186523A (en) | Macrocyclic rip2 kinase inhibitors | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| EA201692020A1 (ru) | Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases |